

Inhibitory action of roxithromycin on histamine release and prostaglandin D₂ production from β -defensin 2-stimulated mast cells

KAORI KASE¹, JIAN HUA², HIDENORI YOKOI¹, KATSUHISA IKEDA¹ and ISAO NAGAOKA²

Departments of ¹Otorhinolaryngology and ²Host Defense and Biochemical Research, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Received November 6, 2008; Accepted December 23, 2008

DOI: 10.3892/ijmm_00000136

Abstract. The long-term, low-dose therapy with the 14-membered macrolides is well known to be effective for treatment of chronic airway inflammation. Although the mode of macrolides on neutrophils, monocytes, and epithelial cells has been investigated, the effect of macrolides on mast cell function is sparsely reported on. We first examined the effect of roxithromycin (RXM) on mast cell functions activated by human β -defensin-2 (hBD-2). In this study, histamine release, prostaglandin D₂ (PGD₂) production, and intracellular Ca²⁺ concentration ([Ca²⁺]_i) were measured in the absence and presence of RXM, using rat peritoneal mast cells stimulated with hBD-2. RXM, at doses of 12.5 and 25 μ g/ml, significantly inhibited the histamine release from mast cells ($p < 0.05$). In addition, PGD₂ production induced by hBD-2 was significantly reduced by RXM at 6.25 ($p < 0.05$) and 12.5 μ g/ml ($p < 0.01$). Furthermore, the hBD-2-induced increase of [Ca²⁺]_i in mast cells was inhibited by 6.25 and 12.5 μ g/ml of RXM ($p < 0.05$). The present findings suggest that RXM modulates mast cell activation induced by hBD-2 via a Ca²⁺ signal pathway, thereby possibly alleviating chronic airway inflammation.

Introduction

Long-term low-dose macrolide therapy was first introduced for the treatment of diffuse panbronchiolitis in the 1980s (1). In the 1990s, it was also an effective treatment for chronic rhinosinusitis (2-4). The efficacy of this macrolide therapy on chronic rhinosinusitis is believed to be due to their anti-inflammatory effects (5), but the precise mechanisms have not been clarified yet.

Chronic rhinosinusitis is a common upper respiratory tract disease (6). Patients complain of continuous rhinorrhea, nasal obstruction, postnasal drainage, hyposmia, and sometimes facial pain and headache. The underlying pathophysiology of chronic rhinosinusitis is postulated to be controlled by a Th1- and/or 2-mediated cascades (7,8). The number of mast cells, eosinophils and IgE-positive cells were significantly increased in a variety of chronic rhinosinusitis (9,10). This inflammatory cascade is initiated by bioactive mediators such as histamines that are secreted mainly from mast cells. A variety of modulatory effects of macrolides on inflammatory cells are shown in *in vitro* studies (5), but the action of macrolides on mast cell functions is not well understood.

Human β -defensin (hBD), an antimicrobial peptide, is predominately expressed at epithelial tissues, where it participates in the host defense by killing invading microorganisms, as well as promoting both innate and adaptive immune responses (11). Among four hBDs identified so far, hBD-2 is mainly expressed in skin as well as in the respiratory and gastrointestinal tracts (12). hBD-2 mRNA was detected in the turbinate mucosa and nasal polyps of patients with chronic sinusitis, but not in normal nasal mucosa (13,14). In addition, hBD-2 peptide was identified in both normal and inflamed maxillary sinuses where it was secreted from the maxillary sinus epithelia (15). A line of studies published by our research groups propose that hBDs modulate the inflammatory responses by recruiting mast cells to inflammation foci and inducing the degranulation as well as prostaglandin production from this cell population (16-19). However, there is no known report on the effect of macrolides on mast cell functions mediated by epithelial cell-derived hBD-2. A novel mechanism of macrolide revealed by the present study may contribute to a better understanding of the clinical effectiveness of long-term low-dose macrolide therapy on inflammatory airway disorders.

Materials and methods

Reagents. Roxithromycin (erythromycin 9-(-O-[2-methoxyethoxy] methyl)oxime; RXM) was purchased from Sigma Chemical Co. (St. Louis, MO). The agent was dissolved in dimethylsulfoxide (DMSO) at a concentration of 200 mg/ml, and then diluted with Tyrode's buffer (26 mM NaCl, 1 mM

Correspondence to: Dr Isao Nagaoka, Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: nagaokai@juntendo.ac.jp

Key words: roxithromycin, mast cell, β -defensin 2, histamine, prostaglandin D₂, intracellular Ca²⁺ concentration

KCl, 2 mM HEPES, 5.6 mM glucose, 1 mM CaCl₂, 0.5 mM MgCl₂, 0.1% bovine serum albumin, pH 7.4). Final concentration of DMSO was less than 0.3% (20). hBD-2 was purchased from Peptide Institute, Inc. (Osaka, Japan). Histamine enzyme immunoassay (EIA) kit was purchased from Oxford Biomedical Research, Inc. (Oxford, MI). Prostaglandin (PG) D₂-MOX EIA kit was obtained from Cayman Chemical Company (Ann Arbor, MI).

Preparation of mast cells. Mast cells were obtained from male Sprague-Dawley rats weighing 400-500 g by lavage of peritoneal cavity with 50 ml of phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.5 mM KH₂PO₄, pH 7.4) containing 0.1% bovine serum albumin. After centrifugation, the cells were suspended in 10 ml of modified Eagle's minimal essential medium (MEM; Sigma) with 10% fetal calf serum (FCS), and layered on 15 ml of 75% Percoll solution (Amersham, Pharmacia Biotech, Uppsala, Sweden). After centrifugation at 600 g for 25 min at room temperature, mast cells were resuspended in MEM with 1% bovine serum albumin, and washed once with Tyrode's buffer without Ca²⁺ and Mg²⁺. Toluidine blue staining was used as purity criterion (90-99%) (16-19).

Measurement of histamine release. Mast cells at 2x10⁵ cells/ml were preincubated at 37°C for 5 min in the absence or presence of RXM (6.25-25 μg/ml), and then stimulated with hBD-2 at 37°C for 5 min in a volume of 100 μl Tyrode's buffer. The reaction was terminated by placing test tubes in an ice-cold water bath, followed by centrifugation at 200 g for 10 min at 4°C. Histamine content in the supernatants was measured by histamine EIA kit according to the manufacturer's instruction. Total cellular histamine was determined using the cell samples that were incubated without hBD-2 at 37°C for 5 min and then sonicated for 30 sec. Histamine release was expressed as the percentage of total cellular histamine.

Measurement of PGD₂. Mast cells at a concentration of 5x10⁵ cell/ml were preincubated at 37°C for 5 min in the absence or presence of RXM (6.25-12.5 μg/ml), and then stimulated with hBD-2 at 37°C for 2 h in a volume of 100 μl Tyrode's buffer. The reaction was terminated by placing test tubes in an ice-cold water bath, followed by centrifugation at 200 g for 10 min at 4°C. The supernatants were used for PGD₂ quantification by an EIA kit, according to the manufacturer's instructions.

Measurement of intracellular Ca²⁺ mobilization. Intracellular Ca²⁺ concentration ([Ca²⁺]_i) was measured by using a fluorometric imaging plate reader (FLIPR) and a Calcium 3 assay kit according to the manufacturer's instructions (Molecular Devices, Sunnyvale, CA). Briefly, 100 μl of mast cell (2x10⁶ cells/ml) suspensions were applied to each well of Biocoat poly-D-lysine 96-well black/clear plate (Becton Dickinson, Meylan Cedex, France), and preincubated at 37°C for 2 h in the absence or presence of RXM (6.25-12.5 μg/ml). Dye solution (100 μl) containing a chelating agent for external Ca²⁺ was added into each well and incubated at 37°C for 1 h. Subsequently, the plates were inserted into a FLIPR, and the fluorescence




Figure 1. Effect of RXM on histamine release from hBD-2-stimulated mast cells. (A) Mast cells were incubated for at 37°C for 5 min without (Resting) or with hBD-2 (0.625-2.5 μg/ml). Histamine release is expressed as a percentage of total cellular histamine. Each bar represents the mean ± SE of 4 separate experiments. (B) Mast cells were preincubated at 37°C for 5 min in the absence or presence of RXM (6.25-25 μg/ml), and then stimulated by 1.25 μg/ml of hBD-2 at 37°C for 5 min. Mast cells were also preincubated in the absence of RXM and further incubated without hBD-2 (Resting). Histamine release is expressed as a percentage of mast cells stimulated in the absence of RXM. Each bar represents the mean ± SE of 3 separate experiments. *p<0.05.

(relative fluorescence unit: RFU) was determined before and after the addition of 50 μl of hBD-2 at the indicated concentrations.

Statistical analysis. Data are expressed as mean ± SE, and analyzed for significant difference by a one-way ANOVA with multiple comparison test (StatView®, Abacus concept, Berkeley, CA). Differences were considered statistically significant at p<0.05.

Results

Evaluation of histamine-releasing activities of hBD-2. To evaluate the histamine-releasing activities of hBD-2, mast cells were incubated with various concentrations of hBD-2. At resting conditions without hBD-2, little response of histamine release was observed (Fig. 1A). hBD-2 induced the histamine release from cultured mast cells in a dose-dependent manner. Since hBD-2 at 1.25 μg/ml increased histamine release ~70%, we performed the following studies using 1.25 μg/ml hBD-2,




Figure 2. Effect of RXM on PGD₂ production from hBD-2-stimulated mast cells. Mast cells were preincubated at 37°C for 5 min in the absence or presence of RXM (6.25-12.5 μg/ml), and then stimulated by 1.25 μg/ml of hBD-2 at 37°C for 2 h. Mast cells were also preincubated in the absence of RXM and further incubated without hBD-2 (Resting). PGD₂ production is expressed as a percentage of mast cells stimulated in the absence of RXM. Each bar represents the mean ± SE of 3 separate experiments. *p<0.05; **p<0.01.

which is considered the most effective dose to evaluate the effect of macrolides.

Effect of RXM on histamine release from hBD-2-stimulated mast cells. We next examined the effect of RXM on histamine release from hBD-2-stimulated mast cells. Mast cells were stimulated by hBD-2 in the presence of various concentrations of RXM. The histamine release from mast cells induced by 1.25 μg/ml hBD-2 was significantly inhibited by the addition of 12.5 and 25 μg/ml RXM (p<0.05), but not by 6.25 μg/ml (Fig. 1B).

Effect of RXM on PGD₂ production in hBD-2-stimulated mast cells. PGD₂ is known as one of the major biological mediators released from mast cells. We examined the actions of RXM on PGD₂ production of mast cells stimulated by 1.25 μg/ml of hBD-2. hBD-2-induced PGD₂ production from mast cells was suppressed by RXM at 6.25 μg/ml (p<0.05) and 12.5 μg/ml (p<0.01)(Fig. 2).

Effect of RXM on hBD-2-induced [Ca²⁺]_i. The final series of experiments were conducted to clarify the underlying mechanism of inhibitory effects of RXM on the histamine release and PGD₂ production from hBD-2-stimulated mast cells. Since it is well known that the intracellular Ca²⁺ signal plays a key role in the process of histamine release and PG biosynthesis of mast cells (21,22), we examined the effect of RXM on [Ca²⁺]_i in mast cells. Stimulation with hBD-2 resulted in the increase of [Ca²⁺]_i in mast cells dose-dependently from 0.3125 to 1.25 μg/ml (Fig. 3A). The addition of RXM at 6.25 and 12.5 μg/ml suppressed the elevation of [Ca²⁺]_i induced by 0.3125 μg/ml hBD-2 (Fig. 3B). Fig. 3C exhibited the average of relative changes in [Ca²⁺]_i in which RXM at 6.25 and 12.5 μg/ml significantly inhibited the hBD-2-induced increase in [Ca²⁺]_i (p<0.05)(Fig. 3C).

Discussion

We previously reported that hBD-2 stimulates rat peritoneal mast cells to mobilize intracellular Ca²⁺ in a G-protein-phos-




Figure 3. Effect of RXM on hBD-2-induced [Ca²⁺]_i. (A) Mast cells were preincubated at 37°C for 2 h without RXM and then incubated with Ca²⁺ fluorescence dye at 37°C for 1 h. The cells were stimulated with various concentrations of hBD-2 (0.3125-1.25 μg/ml) in the external medium chelating Ca²⁺. (B) Mast cells were preincubated at 37°C for 2 h in the absence or presence of RXM (6.25-12.5 μg/ml), and then incubated with Ca²⁺ fluorescence dye at 37°C for 1 h. The cells were stimulated without (Resting) or with 0.3125 μg/ml of hBD-2. (C) The changes in [Ca²⁺]_i are expressed as a percentage of that in mast cells stimulated in the absence of RXM. Each bar represents the mean ± SE of 4 separate experiments. *p<0.05.

pholipase C-dependent manner, resulting in histamine release or PGD₂ production (16,17). We first evaluated the effects of RXM on the biological activities of mast cells stimulated by hBD-2. All of the responses such as histamine release, PGD₂ production, and increased [Ca²⁺]_i by hBD-2-stimulated mast cells were inhibited by RXM. A few experiments reported on the effect of macrolides on mast cell function. Clarithromycin was demonstrated to induce cell death in mast cells (23). In contrast to the present study, Shimane *et al* (24) reported that RXM (~100 μg/ml) did not inhibit histamine release from mouse mast cells stimulated by chemical substances (compound 48/80 and calcium ionophore A23187) and immunologic stimulants using mouse IgE and anti-mouse IgE. The discrepancy between these two experiments may be due to a difference in the source of mast cells, stimulants, administered dose of RXM, experimental conditions, etc.

The present study indicates that the mode of inhibitory effect of RXM on mast cell functions could be explained by the inhibition of the [Ca²⁺]_i increase. The [Ca²⁺]_i increase resulting from stimulus-response coupling of cell surface receptors is composed of two sources, an initial transient derived from

the mobilization from intracellular pool and a subsequent phase of sustained entry from extracellular milieu (25). In the present study, only Ca^{2+} release from intracellular pool was investigated because the assay medium contained a chelating agent for external Ca^{2+} . Therefore, the present study indicates that RXM can inhibit the Ca^{2+} mobilization from internal store.

The pathophysiology of chronic rhinosinusitis is likely multifactorial, namely upper respiratory tract infection, allergy, anatomical anomalies, and immunological deficiencies. Since various pathogens are highly cultured from chronic rhinosinusitis (26), it is easy to suppose that hBD-2 is secreted from sinus mucosa as evidenced by the previous reports (13-15). Mast cells are suggested to play an important role in the formation of nasal polyps and various types of chronic rhinosinusitis not only through IgE-mediated process but also non-IgE-mediated inflammatory events (27,28). hBD-2 derived from the inflamed sinus epithelia is assumed to participate in inflammation by activating mast cells to release histamine and PGD_2 (16-19). Thus, we advocate that an inhibitory effect of RXM on mast cell activation induced by hBD-2 is a novel mechanism of macrolides. In conclusion, the present findings suggest that macrolides alleviate inflammatory reactions by modulating mast cell functions.

Acknowledgements

We thank Dr François Niyonsaba [Department of Atopy (Allergy) Research Center, Juntendo University School of Medicine] for preparation and functional analysis of rat mast cells.

References

- Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A and Kurashima A: Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. *Respiration* 58: 145-149, 1991.
- Hashiba M and Baba S: Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. *Acta Otolaryngol Suppl* 525: 73-78, 1996.
- Ichimura K, Shimazaki Y, Ishibashi T and Higo R: Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. *Auris Nasus Larynx* 23: 48-56, 1996.
- Suzuki H, Shimomura A, Ikeda K, Oshima T and Takasaka T: Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. *Tohoku J Exp Med* 182: 115-124, 1997.
- Suzuki H and Ikeda K: Mode of action of long-term low-dose macrolide therapy for chronic sinusitis in the light of neutrophil recruitment. *Curr Drug Targets Inflamm Allergy* 1: 117-126, 2002.
- Shapiro GG and Rachelefsky GS: Introduction and definition of sinusitis. *J Allergy Clin Immunol* 90: 417-418, 1992.
- Suzuki H, Goto S, Ikeda K, Oshima T, Furukawa M and Takasaka T: IL-12 receptor beta2 and CD30 expression in paranasal sinus mucosa of patients with chronic sinusitis. *Eur Respir J* 13: 1008-1013, 1999.
- Elhini A, Abdelwahab S and Ikeda K: Th1 and Th2 cell population in chronic ethmoidal rhinosinusitis: a chemokine receptor assay. *Laryngoscope* 115: 1272-1277, 2005.
- Carney AS, Tan LW, Adams D, Varelias A, Ooi EH and Wormald PJ: Th2 immunological inflammation in allergic fungal sinusitis, nonallergic eosinophilic fungal sinusitis, and chronic rhinosinusitis. *Am J Rhinol* 20: 145-149, 2006.
- Sobol SE, Fukakusa M, Christodoulopoulos P, Manoukian JJ, Schloss MD, Frenkiel S and Hamid Q: Inflammation and remodeling of the sinus mucosa in children and adults with chronic sinusitis. *Laryngoscope* 113: 410-414, 2003.
- Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schröder JM, Wang JM, Howard OM and Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* 286: 525-528, 1999.
- Harder J, Bartels J, Christophers E and Schroder JM: A peptide antibiotic from human skin. *Nature* 387: 861, 1997.
- Lee SH, Kim JE, Lim HH, Lee HM and Choi JO: Antimicrobial defensin peptides of the human nasal mucosa. *Ann Otol Rhinol Laryngol* 111: 135-141, 2002.
- Chen PH and Fang SY: Expression of human beta-defensin 2 in human nasal mucosa. *Eur Arch Otorhinolaryngol* 261: 238-241, 2004.
- Carothers DG, Graham SM, Jia HP, Ackermann MR, Tack BF and McCray PB Jr: Production of beta-defensin antimicrobial peptides by maxillary sinus mucosa. *Am J Rhinol* 15: 175-179, 2001.
- Niyonsaba F, Someya A, Hirata M, Ogawa H and Nagaoka I: Evaluation of the effects of peptide antibiotics human beta-defensin-1/2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. *Eur J Immunol* 31: 1066-1075, 2001.
- Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H and Nagaoka I: A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. *Immunology* 106: 20-26, 2002.
- Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H and Nagaoka I: Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. *Int Immunol* 14: 421-426, 2002.
- Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, Saito H, Nagaoka I, Ikeda S, Okumura K and Ogawa H: Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. *Eur J Immunol* 37: 434-444, 2007.
- Ito S, Nasu R, Tsujimoto M, Murakami H, Ohtani H and Sawada Y: Effect of macrolide antibiotics on uptake of digoxin into rat liver. *Biopharm Drug Dispos* 28: 113-123, 2007.
- Kawabe H, Hayashi H and Hayaishi O: Differential calcium effects on prostaglandin D_2 generation and histamine release from isolated rat peritoneal mast cells. *Biochem Biophys Res Commun* 143: 467-474, 1987.
- Van Haaster CM, Engels W, Lemmens PJ, Hornstra G, van der Vusse GJ and Heemskerk JW: Differential release of histamine and prostaglandin D_2 in rat peritoneal mast cells: roles of cytosolic calcium and protein tyrosine kinases. *Biochim Biophys Acta* 1265: 79-88, 1995.
- Borszcz PD, Befus D, Moqbel R, Sin DD, Adamko DJ, Man SF and Lacy P: Effects of clarithromycin on inflammatory cell mediator release and survival. *Chemotherapy* 51: 206-210, 2005.
- Shimane T, Asano K, Suzuki M, Hisamitsu T and Suzaki H: Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. *Mediators Inflamm* 10: 323-332, 2001.
- Streb H, Irvine RF, Berridge MJ and Schulz I: Release of Ca^{2+} from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. *Nature* 306: 67-69, 1983.
- Benninger MS, Anon J and Mabry RL: The medical management of rhinosinusitis. *Otolaryngol Head Neck Surg* 117: S41-S49, 1997.
- Pawankar R: Nasal polyposis: an update: editorial review. *Curr Opin Allergy Clin Immunol* 3: 1-6, 2003.
- Hamilos DL, Leung DY, Wood R, Cunningham L, Bean DK, Yasrueel Z, Schotman E and Hamid Q: Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. *J Allergy Clin Immunol* 96: 537-544, 1995.